Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

1

About Dennis Kavelman

Dennis Kavelman Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Dennis Kavelman News

Inovia Capital Partner and Former RIM CFO and COO Dennis Kavelman Joins BenchSci Board of Directors

Sep 9, 2021

09/09/2021 | 08:02am EDT Message : *Required fields Toronto, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BenchSci, a Toronto-based startup focused on increasing the speed and quality of life-saving research, announced that Inovia Capital partner and former Research In Motion (now BlackBerry) CFO and COO Dennis Kavelman is joining its board of directors. Kavelman has been a partner at Inovia Capital since 2018, where he launched the Growth Fund I and leads the firm’s value creation strategy. Thanks to his extensive operational background, he is well-recognized within the tech ecosystem for providing unique perspectives on managing operational hurdles and growing pains. "I have deep respect for Dennis’ distinguished career and the part he played in bringing an unknown tech company to global status," says Liran Belenzon, CEO, BenchSci. "We were once a small startup too, and our current hypergrowth trajectory makes Dennis’ experiences and wisdom invaluable. As we exponentially increase the speed and quality of life-saving R&D, Dennis will be at our side guiding us." Kavelman is an experienced technology executive and investor. After beginning his career at KPMG, he joined RIM in 1995 and, in his roles as CFO and COO, helped the company create the global smartphone industry. During his tenure there, he managed the scaling of a worldwide software, hardware, and services business while overseeing all financing activities, including RIM's IPO and over $1.8B in equity raises. "BenchSci’s suite of AI-powered applications help scientists accelerate preclinical research and gets us closer to novel drug development,” says Kavelman. “They are an emerging biotech global leader and I am excited to be on the team to apply my experience and help in whatever way I can.”  Kavelman joins existing board members Bonita Stewart, Board Partner, Gradient Ventures; Luba Greenwood, Executive Managing Partner at Dana-Farber Cancer Institute; and Shervin Ghaemmaghami, Operating Partner, F-Prime Capital. For more BenchSci updates, visit our news page . About BenchSci  BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. We’re achieving it by empowering scientists with the world’s most advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, our platform accelerates science at 15 top-20 pharmaceutical companies and over 4,300 leading research centers worldwide. We’re a remote-first, CIX Top 10 Growth company, certified Great Place to Work®, and top-ranked company on Glassdoor. Learn more at www.benchsci.com . Attachment

Dennis Kavelman Investments

1 Investments

Dennis Kavelman has made 1 investments. Their latest investment was in Vidyard as part of their Seed VC on November 11, 2011.

CBI Logo

Dennis Kavelman Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/17/2011

Seed VC

Vidyard

$1.65M

Yes

1

Date

11/17/2011

Round

Seed VC

Company

Vidyard

Amount

$1.65M

New?

Yes

Co-Investors

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.